Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Tumor-Agnostic 2Thoracic 2

Conditions

Prostatic Neoplasms 4Castrate-Resistant Prostate Cancer 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × OGX-011 × Genitourinary × Clear all
NCT00138918 2017-03-03

Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

University of British Columbia

Phase 2 Completed
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT01188187 2016-10-14

SYNERGY

Achieve Life Sciences

Phase 3 Completed
1,022 enrolled
Genitourinary

Prostatic Neoplasms

NCT01083615 2016-10-12

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Achieve Life Sciences

Phase 3 Terminated
14 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT01578655 2016-10-12

AFFINITY

Achieve Life Sciences

Phase 3 Completed
630 enrolled
Genitourinary

Prostatic Neoplasms

NCT00327340 2012-10-05

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Achieve Life Sciences

Phase 2 Completed
70 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡